Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum-994

Test info

  
Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum
  
994
  
LAB994
  
MSO
  
Anti-THSD7A
THSD7A
THSD7A Ab, S
Thrombospondin
  

Distinguishing primary from secondary membranous nephropathy cases with antibodies against THSD7A

Specimen

  
Serum
  
  
1.0 mL
  
0.5 mL
  

Immediately following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin 
  
  
  

Immediately following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot
  2. Spin
  3. Transfer the serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum
  4. Refrigerate
  
  

Refrigerated (preferred) - 14 days

Ambient - 8 hours

Frozen - 14 days

  

Gross hemolysis

Performance

  
Mayo Clinic Laboratories (THSD7): R-NX
  
Tu
  
3 - 7 days
  

Indirect Immunofluorescence Assay (IFA)

Clinical and Interpretive info

  

Negative

  

Recently, autoantibodies against phospholipase A2 receptor (PLA2R) in the kidney were determined to be the major target antigen for patients with idiopathic/primary membranous nephropathy (MN). Approximately 70% of patients with primary MN circulate anti-PLA2R antibodies, and in the remaining 30% (who are PLA2R-negative), anti-thrombospondin type-1 domain-containing 7A (THSD7A) was shown to have approximately a 10% prevalence (or about 3% of all primary MN patients). Mouse podocytes express THSD7A and introduction of anti-THSD7A autoantibodies induces MN in murine models. Mouse podocytes do not express PLA2R so exogenous administration of anti-PLA2R does not recapitulate membranous nephropathy in mice. Additionally, THSD7A has been described as a potential tumor antigen and, thus, it has been suggested that THSD7A-positive patients merit a thorough cancer screening.

  
This test should not be used as a stand-alone test but as an adjunct to other clinical information. A diagnosis of primary or secondary membranous nephropathy (MN) should not be made based on a single test result. The clinical symptoms, results on physical examination, and laboratory tests (eg, serological tests), when appropriate, should always be taken into account when considering the diagnosis of primary versus secondary MN.
Absence of circulating autoantibodies does not rule out a diagnosis of primary MN.

Billing

  
86255

Tracking

  
06/13/2023
  
06/14/2023